Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcomaKarin G. Schrenk, Andreas Hochhaus, Christian Spiegel et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 7